Global stability and optimal control for a hepatitis B virus infection model with immune response and drug therapy
In this paper, a nonlinear mathematical model describing the relationship between hepatitis B virus (HBV), the immune response and the drug therapy is studied. Two main equilibrium points (infection-free and endemic) are obtained. The basic reproduction number is also determined and becomes the threshold for equilibrium point stabilities. We show that when the basic reproduction number is less than one, the infection-free equilibrium point is both locally and globally stable whereas when it is greater than one, the system is uniformly persistent i.e. the virus is endemic and the endemic equilibrium point is globally asymptotically stable. The sensitivity analysis is carried out to seek for potential parameters that could reduce overall HBV infection. Further, by using Pontryagin’s minimum principle, the optimal control problem is constructed with two drug therapy controls. Finally, the numerical simulations are established to show the role of these optimal therapies in controlling viral replication and HBV infection. Our results show that the treatment by inhibiting viral production gives more significant result than the treatment by blocking new infection, however the combination of both treatments is the best strategy to reduce overall HBV infection and the concentration of free virus.
KeywordsCytotoxic T lymphocytes Drug therapy Geometric approach Hepatitis B virus Hepatocyte Sensitivity
Mathematics Subject Classification37N25 62P10
This work has been supported by Department of Mathematics, Faculty of Science, Naresuan University, Thailand. Pensiri Yosyingyong has been funded by DPST scholarship from the Thai government.
- 1.WHO (World Health Organiaztion): Hepatitis B fact sheet no. 204. The World Health Organisation, Geneva (2017). Retrieved January 2 (2017), from. http://www.who.int/mediacentre/factsheets/fs204/en/
- 22.Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S.G., Goodman, Z., Wulfsohn, M.S., et al.: Adefovir dipivoxil for the treatment of hepatitis Be antigenNegative chronic hepatitis B. N. Eng. J. Med. 348, 800–807 (2003). https://doi.org/10.1056/NEJMoa021812 CrossRefGoogle Scholar
- 27.Koonprasert, S., Moore, E.J., Banyatlersthaworn, S.: Sensitivity and stability analysis of hepatitis B virus model with non-cytolytic cure process and logistic hepatocyte growth. Glob. J. Pure Appl. Math. 12, 2297–2312 (2016)Google Scholar
- 34.Tridane, A., Hattaf, K., Yafia, R., Rihan, F.A.: Mathematical modeling of HBV with the antiviral therapy for the immunocompromised patients. Commun. Math. Biol. Neurosci. ISSN:2052–2541 (2016)Google Scholar
- 40.Allali, K., Meskaf, A., Tridane, A.: Mathematical modeling of the adaptive immune responses in the early stage of the HBV infection. Int. J. Differ. Equ. Article ID 6710575 (2018)Google Scholar
- 52.Bralet, M.P., Branchereau, S., Brechot, C., Ferry, N.: Cell lineage study in the liver using retroviral mediated gene transfer. Am. J. Pathol. 144, 896–905 (1994)Google Scholar
- 55.Nowak, M.A., May, R.M.: Viral Dynamics. Oxford University Press, Oxford (2000)Google Scholar